Optimizing the Alcyone Trial: Efficacy of Daratumumab And Bortezomib Maintenance in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Post Dara-Vmp Induction, 1 Year Analysis

被引：0

作者：

Tamariz-Amador, Luis Esteban ^{[1
]}

Puertas, Borja ^{[2
]}

Hernandez, Miguel ^{[3
]}

Garcia, Alfonso ^{[4
]}

Jesus Blanchard, Maria ^{[5
]}

Ramirez-Payer, Angel ^{[6
]}

Lerma, Ana ^{[7
]}

Escalante, Fernando ^{[8
]}

Cobo-Rodriguez, Maria Teresa ^{[9
]}

Barez-Garcia, Abelardo ^{[10
]}

Gonzalez-Perez, Marta ^{[11
]}

De Soto, Teresa ^{[12
]}

Suarez-Cabrera, Alexia ^{[13
]}

Martinez-Castro, Margarita ^{[14
]}

Sancho Val, Luis Ignacio ^{[15
]}

Dios Loureiro, Ana ^{[16
]}

Yus Cebrian, Flor ^{[17
]}

Anguita, Magdalena ^{[18
]}

Alonso, Arancha ^{[19
]}

Gimenez Mesa, Eugenio ^{[20
]}

Angel Mendez, Jose ^{[21
]}

Jose Lahuerta, Juan ^{[22
]}

Blade, Joan ^{[23
]}

San-Miguel, Jesus ^{[24
]}

Mateos Manteca, Maria-Victoria ^{[25
]}

机构：

[1] Clin Univ Navarra, IDISNA, Dept Hematol, Pamplona, Spain

[2] Univ Hosp Salamanca, Hematol, Salamanca, Spain

[3] Hosp Univ Canarias, San Cristobal la Laguna, Spain

[4] Hosp Clin Univ Valladolid, Valladolid, Spain

[5] Hosp Univ Ramon & Cajal, Madrid, Spain

[6] Hosp Univ Cent Asturias, Oviedo, Spain

[7] Hosp Univ Gen Nuestra Senora Prado, Talavera De La Reina, Spain

[8] Hosp Univ Leon, Leon, Spain

[9] Hosp Univ Sureste, Madrid, Spain

[10] Complejo Asistencial Avila, Avila, Portugal

[11] Hosp Clin Univ Santiago, Santiago, Chile

[12] Hosp Univ La Paz, La Paz, Mexico

[13] Hosp Univ Gran Canaria Doctor Negrin, Las Palmas Gran Canaria, Spain

[14] Complejo Hosp Univ Vigo, Vigo, Spain

[15] Hosp Clin Univ Lozano Blesa, Zaragoza, Spain

[16] Complejo Hosp Univ Pontevedra, Pontevedra, Spain

[17] Hosp Univ San Jorge, Zaragoza, Spain

[18] Complejo Hosp Jaen, Jaen, Spain

[19] Hosp Univ Ruber Juan Bravo, Madrid, Spain

[20] Hosp Univ Infanta Sofia, Sofia, Bulgaria

[21] Complejo Hosp Univ Orense, Orense, Spain

[22] Hosp Univ 12 Octubre, Madrid, Spain

[23] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[24] Clin Univ Navarra, Navarra, Spain

[25] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, CIBERONC, Salamanca, Spain

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-369

引用

页码：S246 / S247

页数：2

共 50 条

[41] Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)
Ishida, Tadao
Ozaki, Shuji
Kimura, Hideo
Kubo, Koumei
Sunami, Kazutaka
Takezako, Naoki
Fujita, Hiroyuki
Hayashi, Toshiaki
Kiguchi, Toru
Kobayashi, Takeshi
Yamamoto, Satoshi
Takamatsu, Hiroyuki
Kosugi, Hiroshi
Ohta, Kensuke
Sakai, Rika
Handa, Hiroshi
Hisatomi, Takashi
Abe, Yu
Sasaki, Ko
Omoto, Eijiro
Murakami, Hirokazu
Shimizu, Kazuyuki
BLOOD, 2017, 130
[42] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
Joseph, Nisha
Kaufman, Jonathan
Lonial, Sagar
Hofmeister, Craig
Dhodapkar, Madhav
Gupta, Vikas
DiCamillo, Sara
Roberts, Danielle
Boise, Lawrence
Nooka, Ajay
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
[43] Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis
Sun, Chun-yan
Li, Jun-ying
Chu, Zhang-bo
Zhang, Lu
Chen, Lei
Hu, Yu
BIOSCIENCE REPORTS, 2017, 37
[44] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Okazuka, Kiyoshi
Ishida, Tadao
Nashimoto, Junichiro
Uto, Yui
Sato, Kota
Miyazaki, Kanji
Ogura, Mizuki
Yoshiki, Yumiko
Abe, Yu
Tsukada, Nobuhiro
Suzuki, Kenshi
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
[45] Efficacy of daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial.
Avet-Loiseau, Herve
Moreau, Philippe
Attal, Michel
Hulin, Cyrille
Arnulf, Bertrand
Corre, Jill
Garderet, Laurent
Karlin, Lionel
Lambert, Jerome
Macro, Margaret
Perrot, Aurore
Sonneveld, Pieter
Levin, Mark-David
Klein, Saskia
Chiu, Christopher
Pei, Lixia
De Boer, Carla
Kampfenkel, Tobias
Wuilleme, Soraya
Bene, Marie-Christine
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[46] Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Loiseau, Herve Avet
Sonneveld, Pieter
Moreau, Philippe
Offner, Fritz
van der Velden, Vincent H. J.
Caillot, Denis
Hulin, Cyrille
Arnulf, Bertrand
Corre, Jill
Mohty, Mohamad
Karlin, Lionel
Lambert, Jerome
Macro, Margaret
Perrot, Aurore
Levin, Mark-David
Klein, Saskia K.
Stoppa, Anne-Marie
Delforge, Michel
Zweegman, Sonja
Jie, Kon-Siong
Van De Donk, Niels W. C. J.
Krevvata, Maria
Rigat, Fabio
Yang, Shiyi
Vanquickelberghe, Veronique
de Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Wuilleme, Soraya
Broyl, Annemiek
Bene, Marie C.
BLOOD, 2021, 138
[47] Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone: a quadruplet intensified treatment for transplant eligible newly diagnosed Multiple Myeloma (TE NDMM) patients final results
Crusoe, Edvan
Santos, Juliana
Leal, JOanna
Santos, Herbert
Santos, Allan
Almeida, Alessandro
Santos, Mariane
Lucas, Larissa
Queiroz, Sarah
Fonseca, Cleverson
Adorno, Elisangela
Vieira, Lucas
Hungria, Vania
Salvino, Marco
Arruda, Maria da Gloria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S130 - S130
[48] Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
Chari, Ajai
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Silbermann, Rebecca
Costa, Luciano J.
Anderson Jr, Larry D.
Nathwani, Nitya
Shah, Nina
Bumma, Naresh
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Lin, Thomas S.
Voorhees, Peter M.
Usmani, Saad Z.
Richardson, Paul G.
BLOOD CANCER JOURNAL, 2024, 14 (01):
[49] MAINTENANCE THERAPY WITH BORTEZOMIB/DEXAMETHASONE IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS CARRYING HIGH RISK FEATURES
Mancuso, K.
Tacchetti, P.
Pantani, L.
Rocchi, S.
Rizzello, I.
Caratozzolo, I.
De Cicco, G.
Fusco, A.
Testoni, N.
Terragna, C.
Marzocchi, G.
Martello, M.
Borsi, E.
Dozza, L.
Zamagni, E.
Cavo, M.
HAEMATOLOGICA, 2019, 104 : 50 - 50
[50] Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob P.
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca W.
Costa, Luciano J.
Anderson, Larry D.
Nathwani, Nitya
Shah, Nina D.
Efebera, Yvonne A.
Costello, Caitlin L.
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2019, 134

← 1 2 3 4 5 →